无(wu)锡福祈制(zhi)药(yao)有限(xian)公(gong)(gong)司(si)，前身为无(wu)锡市第二(er)制(zhi)药(yao)厂，为江(jiang)苏(su)省(sheng)高新(xin)(xin)技术企业和江(jiang)苏(su)省(sheng)科技创(chuang)新(xin)(xin)型企业, 始建于1943年(nian)，位于风景秀美的(de)太湖之滨。公(gong)(gong)司(si)注(zhu)册资本32000万元(yuan)人(ren)民(min)币(bi)，占地面积100,000平(ping)方米。公(gong)(gong)司(si)主要生产(chan)抗生素原料药(yao)、化学合成原料药(yao)以及口服(fu)固体制(zhi)剂；发酵总量近500立方米，建有8个符(fu)合国(guo)(guo)内国(guo)(guo)际GMP要求的(de)生产(chan)车间。
无锡福祈(qi)制药有限公(gong)司秉承“祈(qi)康(kang)厚生(sheng)，福泽民众”的信(xin)念宗旨，致力于原(yuan)料药和(he)成品药研发和(he)生(sheng)产(chan)，为客(ke)户提供更好的产(chan)品与服(fu)务(wu)。公(gong)司质量管理体系完善，设(she)(she)备仪器(qi)先(xian)进，产(chan)品质量优良(liang)，配(pei)套设(she)(she)施完善。公(gong)司通过(guo)了(le)由国(guo)内外药品监督管理机关组织中囯GMP（2010）及欧洲(zhou)GMP认(ren)证(zheng)，通过(guo)了(le)清洁生产审(shen)核以及中经科环(huan)基于GB/T24001-2016 idt ISO14001：2015 标(biao)准(zhun)的(de)环(huan)境管理体(ti)系(xi)认(ren)证(zheng)；GB/T45001-2020 idt ISO45001：2018 标(biao)准(zhun)的(de)职业健康安全管理体(ti)系(xi)认(ren)证(zheng)。
公司拥有一大批(pi)高技术专业人士组成的人才队伍，从事着管理、科研、开发、生产、营销工作。
企(qi)业(ye)(ye)目前(qian)主要(yao)产(chan)品有硫酸奈替(ti)米星，硫酸西索米星，硫酸核(he)糖霉素及(ji)(ji)螺(luo)旋霉素等抗生(sheng)素药(yao)(yao)物(wu)，吗替(ti)麦考酚酯，他克莫(mo)司等器官移植(zhi)抗排(pai)斥(chi)方面的(de)药(yao)(yao)物(wu)，产(chan)品远销欧(ou)洲(zhou)，美洲(zhou)，非洲(zhou)，及(ji)(ji)东南亚等几十个国(guo)家和(he)地(di)区。得天(tian)独厚(hou)的(de)先天(tian)优势，造(zao)就了企(qi)业(ye)(ye)深(shen)厚(hou)的(de)文化底蕴；雄厚(hou)的(de)科学技术力(li)量，为企(qi)业(ye)(ye)的(de)长足(zu)发展创造(zao)了机(ji)遇。在以(yi)质(zhi)量求生(sheng)存(cun)，以(yi)创新谋发展的(de)经营理念(nian)的(de)指导下，无(wu)锡福祈积极开发治疗器官移植(zhi)抗排(pai)斥(chi)药(yao)(yao)，新型抗肿(zhong)瘤药(yao)(yao)以(yi)及(ji)(ji)保(bao)肝(gan)药(yao)(yao)等一系列的(de)新产(chan)品，并逐渐稳步拓(tuo)展成(cheng)品药(yao)(yao)市场，为企(qi)业(ye)(ye)中长期的(de)发展提供持(chi)久动力(li)。
强大的(de)研发(fa)实力，坚实的(de)生(sheng)产技术，先进的(de)管理理念，创新的(de)经营(ying)思(si)路和不断自我(wo)提升(sheng)的(de)质量管理体系是无锡福祈的(de)竞争优势，企业(ye)正(zheng)努(nu)力把自身建设成为国(guo)内外知名的(de)现代(dai)化制药企业(ye)。
WuxiFortune Pharmaceutical co., LTD is formerly known as Wuxi No. 2 Pharmaceutical Factory, is an new high-tech enterprise and technological innovation-based enterprise in Jiangsu Province. It was established in 1943 and located nearby the beautiful Taihu Lake. The registered capital is 320,000,000 RMB, and the total area is 100,000 m2. The main products are antibiotic APIs, chemical synthesis APIs and oral solid preparations. The total fermentation amount is about 500m3. There are eight workshops complied with the requirements of Current Chinese GMP (2010 version), which is equal to that of EU GMP, WHO GMP and ICH Q7A.
Wuxi Fortune pharmaceutical Co., LTD., adheres to the belief of "pray for the health, improve the living condition, bless the people", devotes to developing and manufacturing API and finished products, and provide better products and services. We have complete quality assurance system, advanced facility, providing good products, and perfect matching facilities. The company has passed the Chinese GMP (2010) Certification and European GMP Certification conducted by domestic and foreign regulatory administration authorities, cleaning production audit, the Environmental Management System Certification (GB/T24001-2016/ISO ISO14001:2015), and the Occupational Health and Safety Management System Certification (GB/T45001-2020/ISO 45001:2018) conducted by Beijing Zhongjing Quality Certification Co., Ltd.
At present, the main products are antibiotics drugs such as Netilmicin Sulfate, Sisomicin Sulfate, Ribostamycin Sulfate, and Spiramycin etc. and immunosuppressant like Mycophenolate Mofetiland Tacrolimus. Most of our products are exported to Europe, America, Africa, and Southeast Asia.
The advantagedsuperiority creates deep enterprise culture and the abundant science and technology strength create the development opportunities. Now Wuxi Fortune develops on the organ transplantation anti-rejection drugs, new antineoplastic and hepatoprotective. We also gradually expand the market of finished drug products to provide enduring power for the enterprise development. Strong research and development strength, firm production technology, advanced management ideas, innovative business ideas and continuous self-improvement quality management system are our competitive advantage. We work hard to make the enterprise become a famous modern pharmaceutical enterprise.
